연구동향 분석
박사

The effect of anti-inflammatory agents on metastatic activity of breast cancer cells = 유방암 전이 기작에서 항염증물질의 효과검증

MANDER SUNAM 2019년

논문상세정보
인용/피인용
' The effect of anti-inflammatory agents on metastatic activity of breast cancer cells = 유방암 전이 기작에서 항염증물질의 효과검증' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • SP-8356
  • breast cancer
  • metastasis
  • nafamostat mesilate
  • nf-kb
  • triple negative breast cancer
  • verbenone
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
715 0

0.0%

' The effect of anti-inflammatory agents on metastatic activity of breast cancer cells = 유방암 전이 기작에서 항염증물질의 효과검증' 의 참고문헌

  • Wu, Y., and Zhou, B. P. (2010) TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion. British Journal of Cancer 102, 639-644.
  • Woolf, D.K., Padhani, A.R., and Makris, A. (2015) Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Annals of Oncology 26:1048-1057.
  • Wang, P., & Sang, S. (2018) Metabolism and pharmacokinetics of resveratrol and pterostilbene. BioFactors (Oxford, England) 44, 16-25, doi:10.1002/biof.1410.
  • Van Antwerp, D. J., Martin, S. J., Verma, I. M., and Green, D. R. (1998) Inhibition of TNFinduced apoptosis by NF-kB. Trends in Cell Biology 8, 107-111.
  • Uwagawa, T., Misawa, T., Tsutsui, N., Ito, R., Gocho, T., Hirohara, S., Sadaoka, S., and Yanaga, K. (2013) Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Am J Clin Oncol 36:44-48.
  • Uwagawa, T., Li, Z., Chang, Z., Xia, Q., Peng, B., Sclabas, G.M., Ishiyama, S., Hung, M.C., Evans, D.B., Abbruzzese, J.L., and Chiao, P.J. (2007) Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer 109:2142-2153.
  • Uchima, Y., Sawada, T., Nishihara, T., Maeda, K., Ohira, M., and Hirakawa, K. (2004) Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells. Pancreas 29:123-131.
  • Thiagalingam, S., Lengaue,r C., Leach, F.S., Schutte, M., Hahn, S.A., Overhauser, J., Willson, J.K., Markowitz, S., Hamilton, S.R., Kern, S.E., Kinzler, K.W., and Vogelstein, B. (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13:343-346.
  • Tang, C.H., Lu, D.Y., Yang, R.S., Tsai, H.Y., Kao, M.C., Fu, W.M., and Chen, Y.F. (2007) Leptin-induced IL-6 production is mediated by leptin receptor, insulin receptor substrate-1, phosphatidylinositol 3-kinase, Akt, NF-kappaB, and p300 pathway in microglia. J Immunol 179:1292-1302.
  • Stingl, J., and Caldas, C. (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7, 791-799.
  • Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., Demeter, J., Perou, C.M., Lonning, P.E., Brown, P.O., Borresen-Dale, A.L., and Botstein, D. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423.
  • Song, G., Ouyang, G., and Bao, S. (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59-71.
  • Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A., and Mcguire, W. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 235:177-182.
  • Singh, J.K., Simoes, B.M., Howell, S.J., Farnie, G., and Clarke, R.B. (2013) Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 15:210.
  • Shukla, S., MacLennan, G. T., Fu, P., Patel, J., Marengo, S. R., Resnick, M. I., and Gupta, S. (2004) Nuclear Factor-κB/p65 (Rel A) Is Constitutively Activated in Human Prostate Adenocarcinoma and Correlates with Disease Progression. Neoplasia (New York, N.Y.) 6, 390-400.
  • Santen, R. J., Song, R. X., McPherson, R., Kumar, R., Adam, L., Jeng, M. H., and Yue, W. (2002) The role of mitogen-activated protein (MAP) kinase in breast cancer. The Journal of steroid biochemistry and molecular biology 80, 239-256.
  • Salvatore, U., Enke, B., Salvatore, S., and Massimino, D. A. (2009) The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy. Current Cancer Drug Targets 9, 32-71.
  • Prat, A., and Baselga, J. (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5:531-542.
  • Perou, C.M., Sorlie, T., Eisen, M.B., Van De Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S.X., Lonning, P.E., Borresen-Dale, A.L., Brown, P.O., and Botstein, D. (2000) Molecular portraits of human breast tumours. Nature 406:747- 752.
  • Parkin, D. M., and Fernandez, L. M. (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12 Suppl 1, S70-80.
  • Paplomata, E., and O’Regan, R. (2014) The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Therapeutic Advances in Medical Oncology 6, 154- 166.
  • Padua, D., and Massague, J. (2009) Roles of TGF[beta] in metastasis. Cell Res 19:89-102.
  • Okamoto, T., Mizoguchi, S., Terasaki, H., and Morioka, T. (1994) Safety of high-dose of nafamostat mesilate: toxicological study in beagles. J Pharmacol Exp Ther 268:639-644.
  • Noguchi, S,, Nakatsuka, M., Konishi, H., Kamada, Y., Chekir, C., and Kudo, T. (2003) Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages. Int Immunopharmacol 3:1335-1344.
  • Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., Jr., and Sledge, G. W., Jr. (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Molecular and cellular biology 17, 3629-3639.
  • Nakatsuka, M., Asagiri, K., Noguchi, S., Habara, T., and Kudo, T. (2000) Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts. Life Sci 67:1243- 1250.
  • Naber, H.P., Wiercinska, E., Pardali, E., Van Laar, T., Nirmala, E., Sundqvist, A., Van Dam, H., Van Der Horst, G., Van Der Pluijm, G., Heckmann, B., Danen, E.H., and Ten Dijke, P. (2012) BMP-7 inhibits TGF-beta-induced invasion of breast cancer cells through inhibition of integrin beta(3) expression. Cell Oncol (Dordr) 35:19-28.
  • Mukherjee, D., and Zhao, J. (2013) The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 3:46-57.
  • Mazzieri, R., and Blasi, F. (2005) The urokinase receptor and the regulation of cell proliferation. Thrombosis and haemostasis 93, 641-646.
  • Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chene, P., De Pover, A., Schoemaker, K., Fabbro, D., Gabriel, D., Simonen, M., Murphy, L., Finan, P., Sellers, W., and Garcia-Echeverria, C. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular cancer therapeutics 7, 1851-1863.
  • Lv, Z.D., Kong, B., Li, J.G., Qu, H.L., Wang, X.G., Cao,W.H., Liu, X.Y., Wang, Y., Yang, Z.C., Xu, H.M., and Wang, H.B. (2013) Transforming growth factor-beta 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition. Oncol Rep 29:219-225.
  • Lu, Y.X., Ju, H.Q., Wang, F., Chen, L.Z., Wu, Q.N., Sheng, H., Mo, H.Y., Pan, Z.Z., Xie, D., Kang, T.B., Chen, G., Yun, J.P., Zeng, Z.L., and Xu, R.H. (2016) Inhibition of the NF-kappaB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Lett 380:87-97.
  • Liedtke, C., Mazouni, C., Hess, K.R., Andre, F., Tordai, A., Mejia, J.A., Symmans, W.F., Gonzalez-Angulo, A.M., Hennessy, B., Green, M., Cristofanilli, M., Hortobagyi, G.N., and Pusztai, L. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281.
  • Levitzki, A., and Klein, S. (2010) Signal transduction therapy of cancer. Molecular aspects of medicine 31, 287-329.
  • Lee, H.O., and Sheen, Y.Y. (1997) Estrogen modulation of human breast cancer cell growth. Arch Pharm Res 20:566-571.
  • Kuo, C. F., Su Anti-inflammatory effects of supercritical carbon dioxide extract and its isolated carnosic acid from Rosmarinus officinalis leaves. J Agric Food Chem 59, 3674-3685, doi:10.1021/jf104837w (2011).
  • Kumar, S., and Weaver, V. M. (2009) Mechanics, malignancy, and metastasis: The force journey of a tumor cell. Cancer metastasis reviews 28, 113-127.
  • Kleiner, D. E., and Stetler-Stevenson, W. G. (1999) Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design. Clinical Breast Cancer 9, 29-33.
  • Kimura, T., Fuchimoto, S., Iwagaki, H., Hizuta, A., and Orita, K. (1992) Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. J Int Med Res 20:343-352.
  • Kessenbrock, K., Plaks, V., and Werb, Z. (2010) Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell 141, 52-67.
  • Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., and Clemons, M. (2009) Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design. Clinical Breast Cancer 9, 29-33.
  • Karin, M. (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436.
  • Ju, C., Song, S., Hwang, S., Kim, C., Kim, M., Gu, J., Oh, Y.-K., Lee, K., Kwon, J., Lee, K., Kim, W.-K., and Choi, Y. (2013) Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clinical Cancer Research 13, 4429-4434.
  • Johnston, S.R., Maclennan, K.A., Sacks, N.P., Salter, J., Smith, I.E., and Dowsett, M. (1994) Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30a:1663-1669.
  • Jiang, R., Xia, Y., Li, J., Deng, L., Zhao, L., Shi, J., Wang, X., and Sun, B. (2010) High expression levels of IKKα and IKKβ are necessary for the malignant properties of liver cancer. International Journal of Cancer 126, 1263-1274.
  • Jakowlew, S.B. (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25:435-457.
  • Iwaki, M., Ino, Y., Motoyoshi, A., Ozeki, M., Sato, T., Kurumi, M., and Aoyama, T. (1986) Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol 41:155-162.
  • Hortobagyi, G.N. (2005) Trastuzumab in the Treatment of Breast Cancer. New England Journal of Medicine 353:1734-1736.
  • Hartman, Z.C., Poage, G.M., Den Hollander, P., Tsimelzon, A., Hill, J., Panupinthu, N., Zhang, Y., Mazumdar, A., Hilsenbeck, S.G., Mills, G.B., and Brown, P.H (2013) Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73:3470- 3480.
  • Hahn, S.A., Schutte, M., Shamsul, H.A.T.M., Moskaluk, C.A., Da Costa, L.T., Rozenblum, E., Weinstein, C.L., Fischer, A., Yeo, C.J., Hruban, R.H., and Kern, S.E. (1996) A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1. Science 271:350-353.
  • Gorrasi, A., Li Santi, A., Amodio, G., Alfano, D., Remondelli, P., Montuori, N., and Ragno, P. (2014) The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface. PLoS One 9, e86352.
  • Gocho, T., Uwagawa, T., Furukawa, K., Haruki, K., Fujiwara, Y., Iwase, R., Misawa, T., Ohashi, T., and Yanaga, K. (2013) Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-kappaB activation for pancreatic cancer. Cancer Lett 333:89-95.
  • Giltnane, J.M., and Balko, J.M. (2014) Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med 17:275-283.
  • Gajria. D., and Chandarlapaty, S. (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11:263-275.
  • Furukawa, K., Iida, T., Shiba, H., Fujiwara, Y., Uwagawa, T., Shimada, Y., Misawa, T., Ohashi, T., and Yanaga, K. (2010) Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model. Oncol Rep 24:843-850.
  • Fujiwara, Y., Furukawa, K., Haruki, K., Shimada, Y., Iida, T., Shiba, H., Uwagawa, T., Ohashi, T., and Yanaga, K. (2011) Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. J Hepatobiliary Pancreat Sci 18:731-739.
  • Fujii, S., and Hitomi, Y. (1981) New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 661:342-345.
  • Foulkes, W.D., Smith, I.E., and Reis-Filho, J.S. (2010) Triple-Negative Breast Cancer. New England Journal of Medicine 363:1938-1948.
  • Egeblad, M., and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174.
  • Dillman, R. O. (1984) Monoclonal antibodies in the treatment of cancer. Critical reviews in oncology/hematology 1, 357-385.
  • Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., and Narod, S. A. (2007) Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clinical Cancer Research 13, 4429-4434.
  • Delgado, L. (2014) Anti-proliferative effects of quercetin and catechin metabolites. Food & function 5, 797-803.
  • Davis, G. E., Pintar Allen, K. A., Salazar, R., and Maxwell, S. A. (2001) Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. Journal of Cell science 114, 917-930.
  • Daub, H., Specht, K., and Ullrich, A. (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nature reviews. Drug discovery 3, 1001-1010.
  • Cui, X., Shen, D., Kong, C., Zhang, Z., Zeng, Y., Lin, X., and Liu, X. (2017) NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo. Scientific Reports 7, 40723.
  • Crown, J., O'shaughnessy, J., and Gullo, G. (2012) Emerging targeted therapies in triplenegative breast cancer. Ann Oncol 23 Suppl 6:vi56-65.
  • Cimica, V., Chen, H. C., Iyer, J. K. & Reich, N. C. (2011) Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importin-beta1. PLoS One 6, 20188.
  • Cho, E.Y., Choi, S.C., Lee, S.H., Ahn JY, Im LR, Kim JH, Xin M, Kwon SU, Kim DK, and Lee YM (2011) Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis. Int Immunopharmacol 11:412-417.
  • Chen, Q., Lin, T. H., Der, C. J., and Juliano, R. L. (1996) Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras. The Journal of biological chemistry 271, 18122-18127.
  • Chambard, J.-C., Lefloch, R., Pouyss gur, J., and Lenormand, P. (2007) ERK implication in cell cycle regulation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1773, 1299-1310.
  • Brandi, G., Tavolari, S., De Rosa, F., Di Girolamo, S., Agostini, V., Barbera, M.A., Frega, G., and Biasco, G. (2012) Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One 7:e41347.
  • Boyle, P. (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23 Suppl 6:vi7-12.
  • Bose, S., Chandran, S., Mirocha, J.M., and Bose, N. (2006) The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19:238-245.
  • Biswas, D. K., Shi, Q., Baily, S., Strickland, I., Ghosh, S., Pardee, A. B., and Iglehart, J. D. (2004) NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proceedings of the National Academy of Sciences of the United States of America 101, 10137-10142.
  • Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., and Birnbaum, D. (2008) How basal are triple-negative breast cancers? Int J Cancer 123:236-240.
  • Benson, J.R. (2004) Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 5:229-239.
  • Bartholomeusz, C., Gonzalez-Angulo, A.M., Liu, P., Hayashi, N., Lluch, A., Ferrer-Lozano, J., and Hortobagyi, G.N. (2012) High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 17:766- 774.
  • Bao, Y.-N., Cao, X., Luo, D.-H., Sun, R., Peng, L.-X., Wang, L., Yan, Y.-P., Zheng, L.-S., Xie, P., Cao, Y., Liang, Y.-Y., Zheng, F.-J., Huang, B.-J., Xiang, Y.-Q., Lv, X., Chen, Q.-Y., Chen, M.-Y., Huang, P.-Y., Guo, L., Mai, H.-Q., Guo, X., Zeng, Y.-X., and Qian, C.-N. (2014) Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle 13, 1958-1969.
  • Andre, F., and Zielinski, C.C. (2012) Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23 Suppl 6:vi46-51.
  • Alfano, D., Franco, P., Vocca, I., Gambi, N., Pisa, V., Mancini, A., Caputi, M., Carriero, M. V., Iaccarino, I., and Stoppelli, M. P. (2005) The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thrombosis and haemostasis 93, 205-211.
  • Akizawa, T., Koshikawa, S., Ota, K., Kazama, M., Mimura, N., and Hirasawa, Y. (1993) Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 64:376-381.